These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26028263)

  • 1. Repletion of Iron Stores With the Use of Oral Iron Supplementation in Patients With Systolic Heart Failure.
    Niehaus ED; Malhotra R; Cocca-Spofford D; Semigran M; Lewis GD
    J Card Fail; 2015 Aug; 21(8):694-7. PubMed ID: 26028263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial.
    Ambrosy AP; Lewis GD; Malhotra R; Jones AD; Greene SJ; Fudim M; Coles A; Butler J; Sharma A; Hernandez AF; Mentz RJ
    J Cardiovasc Med (Hagerstown); 2019 Apr; 20(4):223-225. PubMed ID: 30540649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
    Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
    Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ferric carboxymaltose in patients with heart failure and iron deficiency.
    Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
    N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia.
    Bregman DB; Morris D; Koch TA; He A; Goodnough LT
    Am J Hematol; 2013 Feb; 88(2):97-101. PubMed ID: 23335357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
    Bailie GR
    Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
    Geisser P; Rumyantsev V
    Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of an accelerated intravenous iron regimen in hospitalized patients with advanced heart failure and iron deficiency.
    Reed BN; Blair EA; Thudium EM; Waters SB; Sueta CA; Jensen BC; Rodgers JE
    Pharmacotherapy; 2015 Jan; 35(1):64-71. PubMed ID: 25556867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
    Schröder O; Mickisch O; Seidler U; de Weerth A; Dignass AU; Herfarth H; Reinshagen M; Schreiber S; Junge U; Schrott M; Stein J
    Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
    Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
    Digestion; 2012; 85(1):47-54. PubMed ID: 22179489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
    Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
    Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial.
    Lewis GD; Malhotra R; Hernandez AF; McNulty SE; Smith A; Felker GM; Tang WHW; LaRue SJ; Redfield MM; Semigran MJ; Givertz MM; Van Buren P; Whellan D; Anstrom KJ; Shah MR; Desvigne-Nickens P; Butler J; Braunwald E;
    JAMA; 2017 May; 317(19):1958-1966. PubMed ID: 28510680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency.
    Charles-Edwards G; Amaral N; Sleigh A; Ayis S; Catibog N; McDonagh T; Monaghan M; Amin-Youssef G; Kemp GJ; Shah AM; Okonko DO
    Circulation; 2019 May; 139(21):2386-2398. PubMed ID: 30776909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease.
    Agarwal R; Rizkala AR; Bastani B; Kaskas MO; Leehey DJ; Besarab A
    Am J Nephrol; 2006; 26(5):445-54. PubMed ID: 17035697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: a randomized clinical trial.
    Kochhar PK; Kaundal A; Ghosh P
    J Obstet Gynaecol Res; 2013 Feb; 39(2):504-10. PubMed ID: 22925176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron Deficiency in Heart Failure: An Overview.
    von Haehling S; Ebner N; Evertz R; Ponikowski P; Anker SD
    JACC Heart Fail; 2019 Jan; 7(1):36-46. PubMed ID: 30553903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical re-evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure.
    Packer M; Anker SD; Butler J; Cleland JGF; Kalra PR; Mentz RJ; Ponikowski P; Talha KM
    Eur J Heart Fail; 2024 Jun; 26(6):1298-1312. PubMed ID: 38727791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.